Skip to content
Screener

Candel Therapeutics, Inc. CADL Q4 2025 Annual earnings

Reported March 12, 2026 · After market close

EPS-$0.54Miss by $0.30
EPS estimate-$0.24

Next report

Nov 12, 2026 (in 2 months)
EPS estimate-$0.30

Financials

Q4 2025

Income statement

See full
Operating income-$15.8M-93.5%
Net income-$29.5M-110%
EPS (diluted)-$0.55-41.0%

Balance sheet

See full
Cash & equivalents$119.7M+16.6%
Total debt$2.9M-75.2%
Total equity$51.9M-21.7%
Total assets$125.2M+17.2%

Cash flow

See full
Operating cash flow-$10.6M-81.8%
CapEx$409.0K+13,533%
Free cash flow-$11.0M-88.7%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$310.18M-19.7%
Enterprise value$193.36M-34.5%

Returns & leverage

See full
Return on equity-64.6%-22.6pp
Debt / equity0.1×-0.1×
Current ratio13.5×+10.7×

FAQ

When did Candel Therapeutics, Inc. report Q4 2025 earnings?
Candel Therapeutics, Inc. (CADL) reported Q4 2025 earnings on March 12, 2026 after market close.
What were Candel Therapeutics, Inc.'s Q4 2025 revenue and EPS?
Candel Therapeutics, Inc. reported eps of $-0.54 for Q4 2025.
Did Candel Therapeutics, Inc. beat estimates in Q4 2025?
EPS missed the consensus estimate of $-0.24 by $0.30.
How did Candel Therapeutics, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 35.0% from $-0.40.
Where can I find Candel Therapeutics, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-103126) and the 10-K periodic report (0001193125-26-103134) directly on SEC EDGAR. The filing index links above go to sec.gov.